Genocea Announces Wind Down of Operations and Delisting From NASDAQ
24 mai 2022 08h00 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its...
Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
28 avr. 2022 16h05 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
08 avr. 2022 13h05 HE
|
Genocea Biosciences, Inc.
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward...
Genocea Biosciences to Host Investor Webinar
04 avr. 2022 08h07 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced...
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
14 mars 2022 17h06 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea Provides Fourth Quarter 2021 Corporate Update
10 mars 2022 07h00 HE
|
Genocea Biosciences, Inc.
Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA),...
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
08 mars 2022 17h39 HE
|
Genocea Biosciences, Inc.
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably...
John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors
07 mars 2022 16h05 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
03 mars 2022 08h00 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth...
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 19h50 HE
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...